Bicycle Therapeutics has been granted a patent for polypeptides that bind to CD137, featuring multiple peptide loops attached to a molecular scaffold. The invention includes drug conjugates and methods for treating cancer or inflammation by inhibiting CD137 using specific peptide ligands. GlobalData’s report on Bicycle Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics's grant share as of July 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Cd137-targeting peptide ligands for cancer and inflammation treatment
The patent US12049520B2 outlines a method for treating cancer or inflammation by inhibiting CD137 in patients. This method involves administering a peptide ligand that is specific for CD137, which includes a polypeptide with at least three cysteine residues arranged with two loop sequences. The peptide ligand is designed to form covalent bonds with a molecular scaffold, resulting in the formation of two polypeptide loops. The molecular scaffold specified in the claims is 1,1',1?-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one (TATA). The claims also detail various amino acid sequences for the peptide ligands, including specific sequences identified as SEQ ID NOs 19, 20, 21, 22, 266, and 267.
Additionally, the patent claims encompass the inclusion of effector or functional groups and cytotoxic agents within the peptide ligands. The cancers targeted by this treatment method include adenocarcinoma, squamous cell carcinoma, colorectal carcinoma, Hodgkin's Lymphoma, and various forms of leukemia, such as B chronic lymphocytic leukemia and T acute lymphocytic leukemia. The claims emphasize the potential of this method to provide therapeutic benefits by specifically inhibiting CD137, which may play a role in the progression of these cancers and inflammatory conditions.
To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
